
Unlocking a novel disease modifying mechanism for Parkinson's disease
First-in-class Oral Therapeutics
Grounded in Patient Biology



More than 10 million people worldwide live with Parkinson's disease. Current treatments only address symptoms, while the underlying neuronal cell loss continues to progress. Alpha-synuclein accumulation and aggregation is widely recognized as one of the central driver of neuronal cell loss, yet no alpha synuclein-targeted therapy has so far demonstrated meaningful benefit for patients.
SynclearON is pioneering a new approach, based on a previously unknown intracellular alpha-synuclein clearance pathway, discovered through AI enhanced phenotypic screening of patient derived dopaminergic neurons. This breakthrough revealed a novel druggable molecular target and enabled the development of proprietary small-molecule modulators, creating a first-in-class opportunity for disease modification.

